Navigation Links
Abbott Announces Positive Data From ABSORB Trial on Its Bioresorbable Vascular Scaffold Technology
Date:3/15/2010

ATLANTA, March 15 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced positive 30-day results from the first 101 patients enrolled in the second phase of the ABSORB trial. Patients treated with Abbott's bioresorbable vascular scaffold (BVS), under clinical investigation in Europe, demonstrated no cases of blood clots (thrombosis), no need for repeat procedures (ischemia-driven target lesion revascularization) and a very low rate of major adverse cardiac events (MACE(1) rate of 2.0 percent) at 30 days. These results build on the long-term success Abbott has seen with the BVS technology in the first phase of the ABSORB trial, which has generated positive data on 30 patients out to three years. Data from the second phase of the trial was presented at the American College of Cardiology's 59th annual scientific session in Atlanta.

"The positive 30-day results reaffirm my belief that a device that bioresorbs, or disappears, into the body after restoring blood flow is the next logical step in the treatment of cardiovascular disease," said Patrick W. Serruys, M.D., Ph.D., professor of interventional cardiology at the Thoraxcentre, Erasmus University Hospital, Rotterdam, the Netherlands, and principal investigator for the ABSORB trial. "The continuing positive results of the ABSORB trial and the clinical benefits demonstrated to date by Abbott's bioresorbable technology show promise that a bioresorbable scaffold is on
'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
2. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
3. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
4. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
5. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
6. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
7. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
8. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
9. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
10. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)...  Shares of Aerie Pharmaceuticals, Inc. (NASDAQ: AERI ... the results of the Phase 3 Rocket 1 trail ... failing to meet its end points, compelling data from ... future studies. An analyst report on AERI ... review, analyst summary, valuation, and recommendation can be viewed ...
(Date:4/30/2015)... Calif., April 30, 2015 Abaxis, Inc. (NasdaqGS: ... blood analysis systems, today reported financial results for the ... Fourth quarter and fiscal 2015 overview: ... the fourth quarter, up 33% over last year,s comparable ... year-over-year. , Diluted EPS of $0.50 for the ...
(Date:4/30/2015)... , April 30, 2015  Accuray Incorporated (Nasdaq: ... signed an agreement with MIM Software Inc. to ... ® and CyberKnife ® product portfolios. The ... MIM technology. This is Accuray,s second collaboration with ... of the first iPad-based treatment plan review capability, ...
Breaking Medicine Technology:All is Not Lost for Aerie Pharmaceuticals - VLM Research Issued by BrokerBank Securities, Inc. 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 3Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 4Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 5Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 6Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 7Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 8Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 9Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 10Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 11Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 12Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 13Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 14Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 15Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 16Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 17Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 18Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 19Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 20Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 21Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 22Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 23Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 24Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 2Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 3
... 19, 2011 Health Alert Communications, www.healthalert.net ... HIV/AIDS: The Jennings Report – Redefining the ... by Forensic Review of the Medical Literature , ... distributors of market intelligence. The report ...
... Jennerex, Inc. (San Francisco), a clinical-stage biotherapeutics ... oncolytic products for cancer, today announced the appointment ... vice president, regulatory affairs. Dr. Fritsch will be ... all aspects of regulatory affairs for all Jennerex ...
Cached Medicine Technology:New Study on HIV/AIDS Redefines the Size, Scale, and Scope of Epidemic 2Jennerex Names Ursula Fritsch, PharmD, as Vice President, Regulatory Affairs 2
(Date:5/3/2015)... CA (PRWEB) May 03, 2015 NuevaCare ... MnemeTherapy® at two upcoming area seminars. The first event ... PSA Annual Regional Stroke Conference to be held at ... offered on Wednesday, May 13 during the Dementia Conference ... , “These seminars offer an excellent opportunity to ...
(Date:5/3/2015)... 2015 HealthPostures, a pioneering ergonomics ... its appearance at the , May 5 - 7, ... will exhibit at the conference include its bestselling TaskMate ... solutions is the 6100 TaskMate Executive. Features of the ... adjustable keyboard tray, extended platform work surface and supply ...
(Date:5/2/2015)... BC (PRWEB) May 02, 2015 Vancouver fencing ... will now provide valuable advice to prospective clients related to ... are looking to install railings around their decks and patios. ... several questions that pop up once the person rolls up ... phases of installing a railing in finding a gate that ...
(Date:5/2/2015)... York, NY (PRWEB) May 02, 2015 ... when a deadly natural disaster strikes anywhere on this ... to leverage human sympathy and compassion for their own ... (United States Computer Emergency Readiness Team) issued an ... users “of potential email scams citing the earthquake in ...
(Date:5/2/2015)... On Tuesday April 7th, the patient ... to celebrate improvements in patient care. In 2014 the ... had zero acquired ventilator associated infections, zero central line ... was also recently named a Top Performer by the ... credited the teamwork of staff from all departments involved ...
Breaking Medicine News(10 mins):Health News:NuevaCare Introduces MnemeTherapy® Approach to Care for Elderly Patients with Alzheimer’s, Stroke and Other Types of Neurodegenerative Conditions 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 3Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 3Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 4Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2
... An elevated rate of increase in prostate specific antigen (PSA) ... prostate cancer, according to a new study published in the ... rate of PSA increase prior to treatment (PSA Velocity) is ... high risk of death from prostate cancer. ,According ...
... A ten-day long festival for gays began in the capital ... will showcase over 20 films on homosexuality directed by many ... and a photographic presentation. ,The aim of the ... country where Section 377 of the Indian Penal Code (IPC) ...
... has adopted yet another spiritual ploy to keep her out of ... report to Los Angeles' Century Regional Detention Center by June 5, ... Mary. ,In the past few days Paris has been ... DVD called Innocent. ,Some pals feel that Hilton, who ...
... chemotherapy errors identified in children reach patients, according to ... errors in children . Published in the July 1, ... American Cancer Society, the study concluded that the antimetabolite ... errors, and that errors in drug administration and errors ...
... UK have discovered mutations in the DNA of four ... breast cancer in women . ,The discovery ... at higher-than-average risk of breast cancer so that they ... - the age when routine breast screening now begins. ...
... participating in one of the largest ever Parkinson's disease ... creatine can slow the symptom progression of this ... the brain in which patients develop tremor, slowness of ... one million people in the U.S. Currently, there are ...
Cached Medicine News:Health News:Scientists Identify the Most Significant Single Predictor of Aggressive Prostate Cancer 2Health News:Gay Film Festival Begins in Delhi 2Health News:Most Pediatric Chemotherapy Mistakes Reach Patients 2Health News:UK Scientists Identify Gene Mutations That Trigger Breast Cancer 2Health News:UK Scientists Identify Gene Mutations That Trigger Breast Cancer 3Health News:Emory Participates in Study to Slow Progression of Parkinson's Disease 2
FLEXILOG accessory....
FLEXILOG spare part....
Complete calibration kits are available for both pH and manometry systems....
Flexilog custom medical carts are configured to suite the requirements of FLEXILOG motility system users. With locking wheels and storage drawers, our carts are suitable for any care provider in any ...
Medicine Products: